Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT02400788 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Resminostat
DRUG: Sorafenib

Sponsor

Yakult Honsha Co., LTD